Jpmorgan Chase & CO Mereo Biopharma Group PLC Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 365 shares of MREO stock, worth $1,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares

365

Previous 365 -0.0%

Holding current value

$1,299

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.58 - $4.25 $97,413 - $160,467	-37,757 Reduced 99.04%	365 $1,000
Q1 2024 May 10, 2024	BUY	$2.3 - $4.05 $43,709 - $76,966	19,004 Added 99.4%	38,122 $125,000
Q4 2023 Feb 12, 2024	SELL	$1.19 - $2.42 $135,282 - $275,112	-113,683 Reduced 85.6%	19,118 $44,000
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $196,914 - $285,954	-171,230 Reduced 56.32%	132,801 $171,000
Q2 2023 Aug 11, 2023	SELL	$0.79 - $1.43 $97,250 - $176,035	-123,102 Reduced 28.82%	304,031 $401,000
Q1 2023 May 11, 2023	BUY	$0.71 - $1.22 $200,130 - $343,886	281,874 Added 194.05%	427,133 $303,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $1.01 $66,378 - $134,084	132,757 Added 1061.89%	145,259 $77,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $6,496 - $13,705	7,922 Added 172.97%	12,502 $10,000
Q2 2022 Aug 11, 2022	SELL	$0.33 - $1.69 $2,832 - $14,503	-8,582 Reduced 65.2%	4,580 $5,000
Q1 2022 May 11, 2022	BUY	$1.04 - $1.7 $382 - $625	368 Added 2.88%	13,162 $15,000
Q4 2021 Feb 10, 2022	BUY	$1.51 - $2.59 $14,788 - $25,366	9,794 Added 326.47%	12,794 $21,000
Q3 2021 Nov 12, 2021	BUY	$2.2 - $3.17 $6,600 - $9,510	3,000 New	3,000 $7,000

Others Institutions Holding MREO

# of Institutions

Shares Held

107M

Call Options Held

209K

Put Options Held

479K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $445M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Mereo Biopharma Group PLC Transaction History